Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Immunoglobulins Market.
Trusted Business Insights presents an updated and Latest Study on Immunoglobulins Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Immunoglobulins Market during the forecast period.
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.
Get Sample Copy of this Report @ Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)
We have updated Immunoglobulins Market with respect to COVID-19 Business Impact.
Inquire before buying
This report focuses on the Immunoglobulins market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Immunoglobulins market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.
Global Immunoglobulins Market: Segment Analysis
The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.
Global Immunoglobulins Market: Regional Analysis
The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.
Global Immunoglobulins Market: Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled
- Shire (Takeda Pharmaceutical Company Limited)
- CSL Behring
- Grifols, S.A.
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products Holdings, Inc.
- LFB SA
- Shanghai RAAS Blood Products Co., Ltd.
Immunoglobulins, also referred to as antibodies, are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, these products have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). However, comparatively high product costs and the associated adverse effects, are some of the major factor projected to restrain the adoption of these products in emerging countries.
The report provides qualitative and quantitative insights on immunoglobulin industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The immunoglobulin market segments include route of administration, indication, form, and end user. On the basis of indication, the market is categorized into (primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and others).
On the basis of route of administration, the market is categorized into intravenous (IV) and subcutaneous (SC). On the basis of form, the market can be segmented into liquid and lyophilized. On the basis of end user, the market can be segmented into hospitals, clinics and homecare. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.
Along with this, the report analysis comprises of market dynamics and competitive landscape. Additionally, the report offers insights on the pipeline analysis, overview of regulatory scenario by key regions, key industry developments, number of primary immunodeficiency (PI) patients by key countries and reimbursement scenario.
By Route of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain-Barre Syndrome (GBS)
- Immune Thrombocytopenic Purpura (ITP)
- Multifocal Motor Neuropathy (MMN)
By End User
- North America (the U.S., and Canada)
- Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America
- Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)
Key Industry Developments
In May 2019, the FDA approved the prior approval supplement (PAS) for ADMA Biologics, Inc.s product offering of BIVIGAM and subsequently ADMA announced that it will begin the commercial sales of the product
In April 2019, a novel intravenous immunoglobulin by ADMA Biologics, Inc. to be utilised for the treatment of primary immunodeficiency called Asceniv (Immune Globulin Intravenous, Human -slra 10%, Liquid), received the FDA approval
In May 2018, Kedrion S.p.A and Kamada announced that KEDRAB, an immunoglobulin aimed at the treatment of rabies, was ready for commercial distribution and shipping
Quick Read Table of Contents of this Report @ Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)
Trusted Business Insights
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580